1. Alkermes will host a Q2 financial results conference call on July 29, 2025. 2. The call will provide insights on financial performance and future forecasts. 3. Alkermes develops neuroscience medicines for addiction and psychiatric disorders. 4. Their portfolio includes products for serious mental health conditions. 5. A webcast replay will be available shortly after the live event.
The conference call may provide critical insights, but no significant market-moving news is indicated.
The earnings call is important for investors, but details on financial performance are pending.
Insights from the call will impact immediate trading but may not affect long-term outlook.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Jamie Constantine
Investor Relations
+1 781 873 2402
SOURCE Alkermes plc